Why the study?
Does cumulative anthracycline dose affect late cardiotoxicity (left ventricular dimension and fractional shortening) in survivors of childhood acute lymphoblastic leukemia?
Population
189 survivors of childhood acute lymphoblastic leukemia
Comparison
Anthracycline therapy at varying cumulative doses vs Lower cumulative anthracycline doses and a…
Design
Cohort
Follow-up
median 8.1 years (range, 2.0 to 23.4)
Key result
Cumulative anthracycline doses >300 mg/m2 in childhood leukemia survivors were associated with significantly depressed left ventricular fractional shortening (29.0% vs predicted 33.8%; P=0.0001).
Authors
Loading...
May increase late LV dysfunction risk above 300 mg/m²; leaves open optimal dose thresholds and monitoring in survivors.
Cohort (n=189)
Yes
Does cumulative anthracycline dose affect late cardiotoxicity (left ventricular dimension and fractional shortening) in survivors of childhood acute lymphoblastic leukemia?
p-value: p=.0001
Late cardiotoxicity, indicated by depressed left ventricular fractional shortening and dilatation, is uncommon in childhood leukemia survivors when cumulative anthracycline doses are ≤300 mg/m2.
Nysom et al. (1998) conducted a cohort in childhood acute lymphoblastic leukemia (n=189). Anthracycline therapy vs. Control population and lower dose groups was evaluated on Left ventricular dimension and fractional shortening (p=.0001). Cumulative anthracycline doses >300 mg/m2 in childhood leukemia survivors were associated with significantly depressed left ventricular fractional shortening (29.0% vs predicted 33.8%; P=0.0001).